63 results
Page 2 of 4
6-K
EX-99.1
crczw27g8qkqs5s
28 Nov 23
Report of Foreign Private Issuer
4:01pm
6-K
EX-99.1
8p3t64q
28 Nov 23
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
4:00pm
6-K
EX-99.1
d4vosbu1
27 Nov 23
SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform
4:00pm
6-K
EX-99.1
t7tmn ekq7
22 Nov 23
SciSparc Signs Non-Binding Letter of Intent to Merge with Leading Vehicle Importer Company in Israel
4:01pm
6-K
EX-99.1
t76y saihwnv3iw
31 Oct 23
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
8:15am
6-K
EX-99.1
mpe3 nrbo8q04lhh
24 Oct 23
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
7:54am
D
m1sri s404jzjc
19 Oct 23
$5.03 mm in options, sold $5.03 mm, 1 investor
4:06pm
6-K
EX-99.1
rntnkzmbb4tbgz7a 230
18 Oct 23
Report of Foreign Private Issuer
6:54am
6-K
EX-99.2
rujujce
16 Oct 23
Interim Consolidated Financial Statements
5:00pm
6-K
EX-99.2
jw6prg 0sz
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
EX-99.1
pswgxzdxe vx47
16 Oct 23
SciSparc Ltd. Announces Closing of $5.026 Million Private Placement
4:01pm
6-K
EX-99.1
gy02612wouhimqb
12 Oct 23
SciSparc Ltd. Announces Pricing of $5.026 Million Private Placement
8:48am
6-K
EX-99.1
a09dc70dixn90kbk3nkw
3 Oct 23
SciSparc Granted European Patent for its Core Technology
7:35am
6-K
EX-99.2
xq8iv31oh iot
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
24er3rj
29 Sep 23
SciSparc Announces Expected Implementation of 1-for-26 Reverse Share Split
7:46am
6-K
EX-99.1
av7lnrk
21 Sep 23
SciSparc Announces 1-for-26 Reverse Share Split
6:31am
6-K
EX-99.1
0xpuvvlzs1lyjofq9w
19 Sep 23
SciSparc Engages Investment Bank to Identify Potential Strategic Transaction Opportunities
6:16pm
6-K
EX-99.1
7wefhrqoge8 6eji6s9b
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-99.2
p9czbq6j gkbfuwd9
7 Sep 23
SciSparc Announces Initiation of Randomized Phase IIb Clinical Trial of its Proprietary SCI-110 for Tourette Syndrome
4:01pm
6-K
EX-99.2
2jg1e6lcny sx2
14 Aug 23
SciSparc Ltd. Announces Pricing of $1.3 Million Underwritten Public Offering
4:31pm